SG11202110986YA - Method for purifying fc region-modified antibody - Google Patents
Method for purifying fc region-modified antibodyInfo
- Publication number
- SG11202110986YA SG11202110986YA SG11202110986YA SG11202110986YA SG11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA SG 11202110986Y A SG11202110986Y A SG 11202110986YA
- Authority
- SG
- Singapore
- Prior art keywords
- purifying
- region
- modified antibody
- antibody
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019074738 | 2019-04-10 | ||
PCT/JP2020/015904 WO2020209318A1 (fr) | 2019-04-10 | 2020-04-09 | Procédé de purification d'anticorps modifié en région fc |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110986YA true SG11202110986YA (en) | 2021-11-29 |
Family
ID=72752051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110986YA SG11202110986YA (en) | 2019-04-10 | 2020-04-09 | Method for purifying fc region-modified antibody |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220213140A1 (fr) |
EP (1) | EP3954696A4 (fr) |
JP (1) | JPWO2020209318A1 (fr) |
KR (1) | KR20210149779A (fr) |
CN (1) | CN113906042A (fr) |
AU (1) | AU2020273072A1 (fr) |
BR (1) | BR112021020204A2 (fr) |
CA (1) | CA3136398A1 (fr) |
IL (1) | IL286982A (fr) |
MX (1) | MX2021012251A (fr) |
SG (1) | SG11202110986YA (fr) |
TW (1) | TW202104244A (fr) |
WO (1) | WO2020209318A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
CA2963760A1 (fr) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anticorps anti-myostatine, polypeptides contenant des variants de regions fc, et procedes d'utilisation |
CA3026050A1 (fr) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition pour la prophylaxie ou le traitement de maladies liees a il-8 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
CA2124967C (fr) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Animaux transgeniques non humains capables de produire des anticorps heterologues |
CA2131151A1 (fr) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methodes de production d'elements formant des paires specifiques de liaison |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
EP0754225A4 (fr) | 1993-04-26 | 2001-01-31 | Genpharm Int | Animaux transgeniques capables de produire des anticorps heterologues |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
JPH09506508A (ja) | 1993-12-03 | 1997-06-30 | メディカル リサーチ カウンシル | 組換え結合タンパク質およびペプチド |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CN101987870B (zh) | 2004-07-15 | 2013-07-03 | 赞科股份有限公司 | 优化的Fc变体 |
EP2845865A1 (fr) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Variantes Fc avec liaison altérée en FcRn |
DE602006003695D1 (de) | 2005-01-05 | 2009-01-02 | F Star Biotech Forsch & Entw | Synthetische Immunoglobulindomänen mit in Regionen des Moleküls, die sich von den die Komplementarität bestimmenden Bereichen unterscheiden, modifizierten Bindeeigenschaften |
JP4179517B2 (ja) | 2006-02-21 | 2008-11-12 | プロテノバ株式会社 | イムノグロブリン親和性リガンド |
WO2007097361A1 (fr) * | 2006-02-21 | 2007-08-30 | Protenova Co., Ltd. | Ligand presentant une affinite pour les immunoglobulines |
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
ES2566957T3 (es) | 2007-09-26 | 2016-04-18 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
EP3575317A1 (fr) | 2007-12-26 | 2019-12-04 | Xencor, Inc. | Variants fc avec liaison altérée à fcrn |
TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
JP5229888B2 (ja) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | 弱酸性域での易解離性を向上したプロテインa変異型タンパク質及び抗体捕捉剤 |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
CN103052649B (zh) | 2010-07-29 | 2015-12-16 | Xencor公司 | 具有修改的等电点的抗体 |
MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
WO2012132067A1 (fr) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | Rétention de molécules de liaison d'antigène dans le plasma sanguin et procédé pour modifier l'immunogénicité |
US10065995B2 (en) * | 2011-03-25 | 2018-09-04 | Kaneka Corporation | Protein for affinity-separation matrix |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
SG11201401101XA (en) | 2011-09-30 | 2014-08-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for promoting loss of antigens |
DK2857419T3 (da) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
CA2874721A1 (fr) | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Molecule de liaison d'antigene specifique a un tissu cible |
WO2014145159A2 (fr) | 2013-03-15 | 2014-09-18 | Permeon Biologics, Inc. | Anticorps à charge génétiquement modifiée ou compositions de protéines de ciblage à pénétration améliorée et méthodes d'utilisation |
JP6153801B2 (ja) | 2013-07-23 | 2017-06-28 | 旭化成ホームズ株式会社 | ノズル |
WO2015034000A1 (fr) * | 2013-09-04 | 2015-03-12 | プロテノバ株式会社 | Multimère du domaine de liaison de l'immunoglobuline |
JP2015185254A (ja) | 2014-03-20 | 2015-10-22 | 日立マクセル株式会社 | 非水電解質二次電池 |
CA2963760A1 (fr) * | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anticorps anti-myostatine, polypeptides contenant des variants de regions fc, et procedes d'utilisation |
KR20240058997A (ko) | 2015-12-18 | 2024-05-03 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
-
2020
- 2020-04-09 CN CN202080034720.3A patent/CN113906042A/zh active Pending
- 2020-04-09 EP EP20787324.1A patent/EP3954696A4/fr active Pending
- 2020-04-09 BR BR112021020204A patent/BR112021020204A2/pt unknown
- 2020-04-09 JP JP2021513692A patent/JPWO2020209318A1/ja active Pending
- 2020-04-09 MX MX2021012251A patent/MX2021012251A/es unknown
- 2020-04-09 WO PCT/JP2020/015904 patent/WO2020209318A1/fr unknown
- 2020-04-09 US US17/602,196 patent/US20220213140A1/en active Pending
- 2020-04-09 SG SG11202110986YA patent/SG11202110986YA/en unknown
- 2020-04-09 AU AU2020273072A patent/AU2020273072A1/en active Pending
- 2020-04-09 CA CA3136398A patent/CA3136398A1/fr active Pending
- 2020-04-09 TW TW109111941A patent/TW202104244A/zh unknown
- 2020-04-09 KR KR1020217035897A patent/KR20210149779A/ko active Search and Examination
-
2021
- 2021-10-05 IL IL286982A patent/IL286982A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021012251A (es) | 2021-11-12 |
CN113906042A (zh) | 2022-01-07 |
US20220213140A1 (en) | 2022-07-07 |
CA3136398A1 (fr) | 2020-10-15 |
WO2020209318A1 (fr) | 2020-10-15 |
EP3954696A4 (fr) | 2023-07-26 |
TW202104244A (zh) | 2021-02-01 |
AU2020273072A1 (en) | 2021-12-09 |
BR112021020204A2 (pt) | 2021-12-07 |
KR20210149779A (ko) | 2021-12-09 |
IL286982A (en) | 2021-12-01 |
EP3954696A1 (fr) | 2022-02-16 |
JPWO2020209318A1 (fr) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286982A (en) | A method for purifying an fc region-modified antibody | |
EP3306310A4 (fr) | Procédé de quantification d'anticorps monoclonal | |
EP3294766C0 (fr) | Anticorps humanisé ou fragment de celui-ci spécifique pour cd3 | |
IL281570A (en) | Methods for the purification of multispecific heterodimeric antibodies | |
IL265016B (en) | A method for purifying antibodies | |
EP3845548A4 (fr) | Procédé de purification d'un anticorps ou d'une molécule de type anticorps | |
EP3805246A4 (fr) | Procédé de purification de polypeptide à chaîne longue | |
IL280140A (en) | Antigen purification method | |
EP3521299A4 (fr) | Procédé de purification de protéine recombinée | |
IL282035A (en) | Method for purifying cannabinoids | |
IL272807B2 (en) | A method for cleaning proteins | |
EP3904320A4 (fr) | Procédé de purification d'hexafluorobutadiène | |
EP3291837A4 (fr) | Cocktails d'anticorps monoclonaux pour le traitement d'infections à ebola | |
EP3092002A4 (fr) | Procédé de purification d'anticorps monoclonaux | |
IL277056A (en) | Methods for purifying antibodies | |
EP3375875A4 (fr) | AGENT DE SÉPARATION POUR DES ANTICORPS POLYCLONAUX HUMAINS DE TYPE IgG DÉRIVÉS DE SÉRUM ET PROCÉDÉ POUR LA SÉPARATION D'ANTICORPS POLYCLONAUX HUMAINS DE TYPE IgG DÉRIVÉS DE SÉRUM L'UTILISANT | |
GB201806736D0 (en) | Method for virus purification | |
IL289959A (en) | Antibody purification methods | |
EP3336172A4 (fr) | Procédé de production d'un anticorps monoclonal spécifique d'un antigène | |
EP3738681A4 (fr) | Procédé de fabrication d'un dispositif de purification de gaz d'échappement | |
EP3560571C0 (fr) | Procede de purification de fructose | |
IL258189A (en) | Antibodies from humans against prostate-specific antigen (5I.10) | |
GB201911685D0 (en) | Process for purifying monoclonal antibodies | |
EP4019930A4 (fr) | Procédé de purification d'huiles | |
IL279684A (en) | A method for purifying cysteamine |